Exacerbated Leishmaniasis Caused by a Viral Endosymbiont can be Prevented by Immunization with Its Viral Capsid.

Détails

Ressource 1Télécharger: journal.pntd.0005240.pdf (2006.46 [Ko])
Etat: Public
Version: de l'auteur
ID Serval
serval:BIB_18963158FCAB
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Exacerbated Leishmaniasis Caused by a Viral Endosymbiont can be Prevented by Immunization with Its Viral Capsid.
Périodique
PLoS Neglected Tropical Diseases
Auteur(s)
Castiglioni P., Hartley M.A., Rossi M., Prevel F., Desponds C., Utzschneider D.T., Eren R.O., Zangger H., Brunner L., Collin N., Zehn D., Kuhlmann F.M., Beverley S.M., Fasel N., Ronet C.
ISSN
1935-2735 (Electronic)
ISSN-L
1935-2727
Statut éditorial
Publié
Date de publication
2017
Peer-reviewed
Oui
Volume
11
Numéro
1
Pages
e0005240
Langue
anglais
Résumé
Recent studies have shown that a cytoplasmic virus called Leishmaniavirus (LRV) is present in some Leishmania species and acts as a potent innate immunogen, aggravating lesional inflammation and development in mice. In humans, the presence of LRV in Leishmania guyanensis and in L. braziliensis was significantly correlated with poor treatment response and symptomatic relapse. So far, no clinical effort has used LRV for prophylactic purposes. In this context, we designed an original vaccine strategy that targeted LRV nested in Leishmania parasites to prevent virus-related complications. To this end, C57BL/6 mice were immunized with a recombinant LRV1 Leishmania guyanensis viral capsid polypeptide formulated with a T helper 1-polarizing adjuvant. LRV1-vaccinated mice had significant reduction in lesion size and parasite load when subsequently challenged with LRV1+ Leishmania guyanensis parasites. The protection conferred by this immunization could be reproduced in naïve mice via T-cell transfer from vaccinated mice but not by serum transfer. The induction of LRV1 specific T cells secreting IFN-γ was confirmed in vaccinated mice and provided strong evidence that LRV1-specific protection arose via a cell mediated immune response against the LRV1 capsid. Our studies suggest that immunization with LRV1 capsid could be of a preventive benefit in mitigating the elevated pathology associated with LRV1 bearing Leishmania infections and possibly avoiding symptomatic relapses after an initial treatment. This novel anti-endosymbiotic vaccine strategy could be exploited to control other infectious diseases, as similar viral infections are largely prevalent across pathogenic pathogens and could consequently open new vaccine opportunities.

Pubmed
Web of science
Open Access
Oui
Création de la notice
24/01/2017 14:32
Dernière modification de la notice
20/08/2019 13:49
Données d'usage